812642-73-2

Basic information

• Product Name: (4-formyl-2,6-dimethoxyphenoxy)acetic acid
• CAS NO: 812642-73-2
• Molecular Formula: C₁₁H₁₂O₆
• Molecular Weight: 240.2094
• Mol File: 812642-73-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 424.3°C at 760 mmHg
• Flash Point: 166.2°C
• Density: 1.303g/cm³
• Vapor Pressure: 5.88E-08mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: (4-formyl-2,6-dimethoxyphenoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4-formyl-2,6-dimethoxyphenoxy)acetic acid(812642-73-2)
• EPA Substance Registry System: (4-formyl-2,6-dimethoxyphenoxy)acetic acid(812642-73-2)

Safety Data

• Hazardous Substances Data: 812642-73-2(Hazardous Substances Data)

Usage

General Description

(4-formyl-2,6-dimethoxyphenoxy)acetic acid is a chemical compound with the molecular formula C11H12O6. It is a derivative of acetic acid and contains a formyl group and two methoxy groups attached to a phenoxy ring. (4-formyl-2,6-dimethoxyphenoxy)acetic acid is commonly used in organic synthesis and pharmaceutical research, and its derivatives have shown potential as anti-inflammatory and antiproliferative agents. Additionally, (4-formyl-2,6-dimethoxyphenoxy)acetic acid has been studied for its potential application in the treatment of various diseases, including cancer, inflammation, and cardiovascular disorders. Its unique chemical structure and reactivity make it a valuable compound for developing new drugs and understanding biological processes at the molecular level.

Upstream product

• 79-11-8 chloroacetic acid 
• 134-96-3 syringic aldehyde 

Relevant articles and documents

Design, synthesis, and biological evaluation of thiazolidine-2,4-dione conjugates as PPAR-γ agonists

A library of synthesized conjugates of phenoxy acetic acid and thiazolidinedione 5a-m showed potent peroxisome proliferator activated receptor-γ (PPAR-γ) transactivation as well as significant blood glucose lowering effect comparable to the standard drugs pioglitazone and rosiglitazone. Most of the compounds showed higher docking scores than the standard drug rosiglitazone in the molecular docking study. Compounds 5l and 5m exhibited PPAR-γ transactivation of 54.21 and 55.41%, respectively, in comparison to the standard drugs pioglitazone and rosiglitazone, which showed 65.94 and 82.21% activation, respectively. Compounds 5l and 5m significantly lowered the blood glucose level of STZ-induced diabetic rats. Compounds 5l and 5m lowered the AST, ALT, and ALP levels more than the standard drug pioglitazone. PPAR-γ gene expression was significantly increased by compound 5m (2.00-fold) in comparison to the standard drugs pioglitazone (1.5-fold) and rosiglitazone (1.0-fold). Compounds 5l and 5m did not cause any damage to the liver and could be considered as promising candidates for the development of new antidiabetic agents.